News Current position: Home > ABOUT US > News

Celetrix Exhibits at the NYC International Cancer Immunotherapy Conference

Hits:Updatetime:2016-09-27 22:09:03【Print】【Close】

Celetrix showcased the latest immunotherapy applications of the advanced electroporation technology in the NYC cancer immunotherapy conference (conference link). In addition to transfection of DNA into T cells with the highest efficiency, Celetrix has achieved an extremely high efficiency of mRNA transfection at 97.5% and the expression level can be controlled.

Experts from US, Canada, UK and China expressed their interests in T cell electroporation, large scale protein production and cell fusion for antibody discovery. Currently trials are available only in the US and China. Researchers from other countries are encouraged to find a colleague or collaborator in the US or China as a surrogate for trials.